Referring a CIDP Patient
Health plans review immune globulin for CIDP against their own criteria, and the published policies of four large commercial plans ask for much the same: electrodiagnostic findings consistent with CIDP, a progressive or relapsing course of at least 2 months, documented functional impairment, and, at renewal, documented improvement. MedRx's intake team works with the neurology practice to send the plan what it asks for and handles the prior authorization.
What plans usually ask for at the first request
Electrodiagnostic studies
All four policies ask for electrodiagnostic findings consistent with CIDP, such as prolonged motor distal latency, reduced motor conduction velocity or partial motor conduction block. Aetna's specialty pharmacy bulletin asks for pre-treatment EMG or nerve conduction studies; Cigna asks for documentation.
Course of the disease
UnitedHealthcare and Aetna ask for symptoms that have progressed, or relapsed and remitted, for at least 2 months; Anthem's definition of typical CIDP also says "over at least 2 months".
Who prescribes
UnitedHealthcare and Cigna require that the medicine be prescribed by or in consultation with a neurologist. Aetna's and Anthem's policies do not state one.
Functional impairment
Aetna asks for moderate to severe functional disability; Anthem for objective functional impairment, such as needing support to walk or upper-limb symptoms that limit function; UnitedHealthcare for a history and physical examination documenting the severity of the condition.
Other causes ruled out
Anthem asks that other causes of neuropathy be ruled out, among them drug- or toxin-induced neuropathy, Lyme disease, IgM neuropathy, hereditary neuropathy, multifocal motor neuropathy and diabetic neuropathy.
Earlier treatments
None of the four policies requires corticosteroids or plasma exchange before immune globulin for CIDP. Some require a preferred immune globulin product first.
Approval periods and renewal
The first approval is short at most plans: 3 months at Aetna and Cigna, 12 weeks at Anthem, and up to 12 months at UnitedHealthcare. Renewal asks for documented improvement:
- UnitedHealthcare: a positive clinical response measured by an objective scale, such as the Rankin, modified Rankin or Medical Research Council (MRC) scale.
- Aetna: significant improvement in disability, maintained since therapy began, with immune globulin used at the lowest effective dose and frequency; re-authorization for 6 months.
- Cigna: a clinically significant improvement in neurologic symptoms, as determined by the prescriber; approval for 1 year. Its examples include improved disability, improved or stable nerve conduction studies, and better strength, such as grip strength, and sensation.
- Anthem: a clinically significant improvement in neurological symptoms on examination, and continued need, for example a stable response on the current dose or worsening when the dose is lowered or the interval lengthened; continuation for 1 year.
Recording a baseline score at the start makes the improvement easier to document at renewal.
SCIG for maintenance
All four policies cover subcutaneous immune globulin for CIDP under the same criteria as IVIG. Cigna limits it to patients 18 years and older, as maintenance therapy in adults. Anthem's criteria published in February 2026 ask for a trial of IVIG, with an inadequate response or intolerance, before a preferred SCIG product; check the plan's current version. Hizentra and HyQvia are FDA-approved for CIDP maintenance in adults after treatment with intravenous immune globulin. See subcutaneous immune globulin for CIDP.
Where the infusions happen
Several plans apply a site-of-care policy to immune globulin: after the first dose, infusions move out of the hospital outpatient department to a non-hospital setting, such as the patient's home, unless a hospital setting is medically necessary. UnitedHealthcare's policy, effective 1 October 2026, names IVIG and SCIG and lists home infusion as an alternative. When a plan asks for the move, the practice can refer the patient to MedRx for infusion at home. See CIDP treatment at home.
What to send MedRx
- the prescription and the Immunoglobulin Referral Form (PDF), which asks for IVIG or SCIG and the product, or lets the pharmacist select the brand
- recent clinical notes that document the course of the disease and the patient's functional impairment, with a baseline score if one was recorded
- the electrodiagnostic report (nerve conduction studies or EMG)
- laboratory results and other tests, including those that rule out other causes of neuropathy
- the treatments tried before, and the patient's insurance information
Send them by fax, or call; how to refer has the numbers and the other ways to send a referral.
The CIDP treatments MedRx dispenses
Gammagard Liquid
IV immune globulin, FDA-approved for CIDP.
Gamunex-C
IV immune globulin, FDA-approved for CIDP.
Panzyga
IV immune globulin, FDA-approved for CIDP in adults.
Privigen
IV immune globulin, FDA-approved for CIDP.
Hizentra
Subcutaneous immune globulin, for CIDP maintenance in adults.
HyQvia
Subcutaneous immune globulin with hyaluronidase, for CIDP maintenance in adults.
Vyvgart Hytrulo
Efgartigimod alfa and hyaluronidase, injected under the skin, FDA-approved for CIDP in adults; not an immune globulin.
How MedRx handles the referral
MedRx's intake team verifies the patient's benefits, obtains prior authorization when the plan requires it, and coordinates with the practice on anything the plan asks for. The medication and supplies are delivered to the patient's door at no charge; a skilled, trusted and licensed nurse from an accredited nursing agency gives each IVIG infusion at home, or trains the patient or caregiver to give SCIG; and a MedRx pharmacist is available 24 hours a day, 7 days a week. MedRx's pharmacy team includes Ig Certified Pharmacists (IgCP).
Key facts
- Organization
- MedRx Infusion Clinical Pharmacy
- What we do
- A home infusion pharmacy and specialty pharmacy, with infusion nurses who visit patients at home and a pharmacist on call 24 hours a day, 7 days a week.
- Where
- Pharmacy at 417 N Oak St, Inglewood, CA 90302. Licensed in 44 states, the District of Columbia and Puerto Rico. See every place we serve
- Accreditation
- URAC (Specialty Pharmacy) and ACHC (Accreditation Commission for Health Care).
- Phone, 24 hours
- (844) 671-2600
- Fax
- (844) 671-2601
Accurate as of
Questions about referring a CIDP patient
01Do health plans require a neurologist for IVIG in CIDP?
Some do. UnitedHealthcare and Cigna require that the medicine be prescribed by or in consultation with a neurologist; Aetna's and Anthem's policies do not state one.
02Do plans require steroids or plasma exchange before IVIG for CIDP?
None of the four published policies read for this page requires corticosteroids or plasma exchange first. Some require a preferred immune globulin product.
03How long does a first approval for CIDP last?
3 months at Aetna and Cigna, 12 weeks at Anthem, and up to 12 months at UnitedHealthcare, in their current policies. Renewal asks for documented improvement.
04Is SCIG covered for CIDP maintenance?
Under the same criteria as IVIG in all four policies; Cigna limits it to adults, and Anthem's February 2026 criteria ask for a trial of IVIG first. Hizentra and HyQvia are FDA-approved for CIDP maintenance in adults.
05How does a neurology practice start a referral?
Send the prescription and the Immunoglobulin Referral Form with the clinical notes, the electrodiagnostic report and laboratory results. MedRx's intake team verifies benefits, obtains prior authorization and coordinates delivery and nursing.
References
- UnitedHealthcare, Immune Globulin (IVIG and SCIG), Medical Benefit Drug Policy 2026D0035AV (PDF) (effective October 1, 2026)
- Aetna, Parenteral Immunoglobulins, Clinical Policy Bulletin 0206 (last reviewed October 8, 2026)
- Aetna, IVIG specialty pharmacy criteria, SGM 2042-A
- Aetna, SCIG specialty pharmacy criteria, SGM 2043-A
- Cigna, Immune Globulin – Intravenous, IP0776 (PDF) (effective September 3, 2026)
- Cigna, Immune Globulin – Subcutaneous, IP0777 (PDF) (effective September 3, 2026)
- Anthem/Elevance, Immunoglobulins, Clinical Criteria CC-0003 (PDF) (published February 1, 2026)
Send a referral
Intake handles benefits investigation, prior authorization and scheduling.
Send a referralFax
(844) 671-2601
Send a completed referral form
